One strategy in the development of anticancer therapeutics has been to arrest malignant proliferation through inhibition of the enzymatic activity of cyclin-dependent kinases (cdks), which are key regulatory molecules of the cell cycle. Over the past few years, numerous compounds with remarkable cdk inhibitory activity have been studied in cancer therapy, although it is very difficult to point out the best cdk to target. An excellent candidate appears to be cdk2, whose alteration is a pathogenic hallmark of tumorigenesis. The small molecule described in our study showed an inhibitory effect on the kinase activity of cdk2, a significant growth arrest observed in a colony formation assay and a reduction in the size of the tumor in nude mice, thus suggesting its potential role as a promising new type of mechanism-based antitumor drug, also for the treatment of hyperproliferative disorders.
Introduction
Cell cycle progression is driven by the coordinated regulation of the activities of a family of protein kinases, the cyclin-dependent kinases (cdks) and their heterodimeric cyclin partners (MacLachlan et al., 1995) . Cdks exert their activity in concert with cyclins through highly controlled phosphorylation of specific target substrates on serine/threonine residues (Lees et al., 1991; Resnitzky and Reed, 1995) . In mammalian cells, the transition from G 1 to S phase is regulated by complexes between D-type cyclins and either cdk4 or cdk6 and between cyclin E or cyclin A and cdk2 (Giordano et al., 1989; Giordano et al., 1991; Koff et al., 1992; Bates et al., 1994) . The activity of cdks is negatively regulated by changes in their phosphorylation status as well as direct association with cyclin-dependent kinase inhibitors (CKIs) (Xiong, 1996) . The INK and the CIP/KIP family of CKIs bind either cyclins or cdks inhibiting their activity, leading to cell cycle progression. Neoplastic transformation leads to the abrogation of cell cycle checkpoints that follows deregulation of cdk/cyclin complex activity, and the loss of cdk inhibitor function (Weinberg, 1995) . Therefore, CKI overexpression is associated with cellular growth arrest in the G 1 phase of the cell cycle, and CKI loss has been described to be critical in oncogenesis (Kamb et al., 1994; Nobori et al., 1994) . Consequently, pharmacological compounds like small molecules targeting specific cdks are potential points of intervention for drug discovery and have been the focus of great interest in cancer therapy. The mechanism of action of molecules capable of inhibiting cdks is to block cell cycle progression through modulation of transcription (Chao et al., 2000) or to induce cell death by downregulation of various antiapoptotic proteins (Li et al., 2000; Pepper et al., 2001) . Over the last decade, several pharmacological cdk inhibitors with strong antitumor activity have been described. However, only a few of these agents are currently undergoing preclinical and clinical evaluation (Fischer and GianellaBorradori, 2003) . Cyclin-dependent kinase 2 (cdk2) is considered the prototypic cell cycle kinase and plays a crucial role in the regulation of cell cycle progression in mammalian cells (Koff et al., 1992; Ohtsubo et al., 1995) . Cdk2 is necessary to pass the G 1 restriction point and to drive cells into DNA replication. This enzyme determines whether a cell will leave its resting phase and enter the S phase, a critical determining point, after which a cell is committed to divide. Cdk2 activity is regulated by several mechanisms, such as binding of cdk inhibitors like p21 waf1 , p27
Kip1 and p57 Kip2 (Malumbres and Barbacid, 2005) , temporal association with cyclins A and E as well as phosphorylation of specific threonine and tyrosine residues (Gu et al., 1992) . Constitutive activation of cyclin E/cdk2 complexes has been often associated with G 1 /S deregulation and tumor progression (Harwell et al., 2004; Liao et al., 2004; Sunters et al., 2004) . Among the target substrates that cdks phosphorylate are the members of the retinoblastoma (Rb) family proteins, which play a pivotal role as negative regulators of cell cycle progression (Claudio et al., 1994; Caputi et al., 2005; Gallo and Giordano, 2005) . This family includes the product of the Rb susceptibility gene, the pRb/p105 protein and the related p107 and pRb2/130 proteins (Mayol et al., 1993; Du and Pogoriler, 2006; Merola et al., 2006) . They share the ability to recruit chromatin-remodeling enzymes and their best characterized targets are the members of the E2F/DP family of transcription factors, generally referred to as E2F (Cinti et al., 2005; Tosi et al., 2005; Genovese et al., 2006; Macaluso et al., 2006; Purev et al., 2006) . Both pRb2/p130 and p107 are able to bind cdk2/ cyclins A and E (Claudio et al., 1996) . We have previously described the cdk2-dependent kinase inhibitory activity shown by the pRb2/p130 spacer domain, which suggests that part of its growth regulatory function could be mediated by the inhibition of this important cell cycle kinase (De Luca et al., 1997) . A similar cdk2 inhibition has been described for p107 (Zhu et al., 1995a, b; Woo et al., 1997) , even though it has been suggested that p107 more likely acts as a competitor by masking cdk2/cyclin A from its substrate, E2F4, rather than being a true cdk inhibitor. In the present study, we have successfully isolated and characterized a specific active component of the Rb2/ p130 gene that appears to be responsible for its growth suppressive activity. The gene component is shown to encode a small, 39-amino-acid polypeptide (Spa310) that is able to greatly inhibit cdk2-dependent histone phosphorylation, halting cellular growth by arresting cells in the G 0 /G 1 phase of the cell cycle. Moreover, the small molecule shows the ability to suppress tumor formation in nude mice, confirming that Spa310 could be an excellent candidate in a mechanism-based approach in cancer therapy, either as an alternative to or in conjunction with other conventional therapies.
Results
Identification of pRb2/p130 sequences required for cdk2 inhibitory activity Several constructs containing different portions of the pRb2/p130 spacer region were consecutively prepared, expressed as glutathione-S-transferase (GST) fusion proteins and tested for their kinase inhibitory activity ( Figure 1 and Table 1 ). Cdk2 immunocomplexes were precipitated from lysates of exponentially growing NIH/ 3T3 cells. Each GST fusion protein was added to the immunoprecipitate and the mixture was subjected to a kinase assay using histone H1 as a substrate. Three GST fusion proteins containing different regions of the spacer domain (Spa, Spb and Spc) were created. We found that an inhibitory effect on histone H1 phosphorylation was exerted only by the first segment (Spa) (see Table 1 ). Three additional mutants derived from the Spa construct (Spa1, Spa2 and Spa3) were developed and tested. We found that the constructs Spa1, Spa2 and Spa3 proved to have little or no inhibitory effect on the cdk2 activity compared to the immunoprecipitates treated with GST alone and the GST-spacer fusion protein. Therefore, two other constructs (Spa12 and Spa23) overlapping the central part of the Spa region were generated and tested. As only the GST fusion protein containing the Spa23 fragment was able to inhibit cdk2 activity, several constructs were finally developed and tested for kinase inhibitory activity by deleting segments of the 5 0 and 3 0 ends of the Spa23 (Spa72, Spa92, Spa38, Spa311, Spa310 and Spa312). Figure 1 shows the effects on cdk2 activity exhibited by the seven final constructs. The Spa310 construct, spanning the region between the amino acids 641 and 679 (39 aa), represents the smallest molecule able to maintain the specific inhibitory ability of the pRb2/p130 spacer domain on cdk2 activity in vitro.
Spacer and Spa310 molecules are localized in both the nucleus and cytoplasm Given the small molecular weight of the 39 aa Spa310 molecule, we evaluated its expression and localization, similarly to the full-length spacer fragment, by using immunofluorescence assay. NIH/3T3 cells were seeded onto Nunc two-well micro-chamber slides (Naperville, IL, USA) and the next day were transiently transfected with pEF6/V5-spacer, pEF6/V5-Spa310 or the control vector pEF6/V5. At 48 h after transfection, cells were analysed for immunofluorescence localization of spacer and Spa310 expression, using a monoclonal antibody Relative cdk2 activity Figure 1 Spa310 construct maintains the inhibitory effects of the pRb2/p130 spacer domain on cdk2 kinase activity. Cdk2 was immunoprecipitated with anti-cdk2 polyclonal antibody from exponentially growing NIH/3T3, incubated with equal amounts of GST fusion proteins in a kinase reaction mixture and assessed for phosphorylation ability of the histone H1 substrate. Proteins were resolved on 10% polyacrylamide gel and the effect on cdk2 activity was visualized by autoradiography. The relative kinase activity values shown represent an average of three independent experiments. pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al that specifically recognizes the V5 tag carried by the transfected constructs. Figure 2 shows that the tagged proteins are strongly expressed in the transfected NIH/ 3T3 cells. The molecules' expression was detected both in the cytoplasm and in the nucleus (red foci) of the transfected cells. The red foci were absent in cells transfected with the control vector, indicating specificity of the immunostaining. Similarly, red foci were absent in non-transfected cells (data not shown).
The Spa310 small molecule inhibits endogenous cdk2 activity The finding that both pRb2/p130 spacer and Spa310 strongly and similarly inhibited cdk2 activity in vitro prompted us to investigate their effect on endogenous cdk2 activity. In order to do that, we transiently transfected NIH/3T3 cells with pEF6/ V5-spacer, pEF6/V5-Spa310 or the control vector pEF6/V5. At 48 h after transfection, endogenous cdk2 Abbreviations: P, positive; N, negative. Nucleotide and amino-acid positions, and the fragment length (in base pairs and amino acids) of deletion mutants based on the sequence of the pRb2/p130 spacer domain are shown. The constructs listed in bold, also represented with the black bars, demonstrated a positive inhibitory effect on cdk2 activity. No significant inhibitory effect on cdk2 activity was detected in the other constructs.
pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al was immunoprecipitated and assayed for kinase activity using histone H1 as a substrate. Figure 3 shows a significant inhibition of cdk2-dependent histone phosphorylation mediated by both the spacer domain and the Spa310 small peptide expression. Although not as potent an inhibitor as the spacer domain, the Spa310 small molecule nevertheless notably inhibited the kinase activity of cdk2.
Spa310 triggers suppression of cell growth observed by colony formation assay
The crucial role of cdk2 activity is known to induce the expression of cell cycle-regulatory genes, thus leading to cell cycle progression (Chae et al., 2004; Yu et al., 2004) . Therefore, inhibiting the phosphorylation ability of this kinase with the Spa310 small molecule is likely to induce cell cycle arrest. Having identified residues that appeared to be critical for the inhibition of cdk2 activity, we determined if these residues were in fact sufficient for cell growth inhibition. The effects of pRb2/p130 spacer domain and the Spa310 small peptide overexpression on cellular growth were examined by colony formation assays. As represented in Figure 4 , the spacer region caused a decrease on the ability of the cells to form colonies of about 50% and the Spa310 of about 60%. The control vector alone had no effect on the clonogenic capacity of the cells, demonstrating that both the spacer and the small molecule are indeed responsible for the growth-inhibited phenotype.
The Spa310 small molecule maintains the growth arrest properties of the full-length spacer leading to an arrest in the G 0 /G 1 phase of the cell cycle Through flow cytometry analyses, we examined whether the inhibition of cdk2 activity caused by the spacer and the Spa310 small molecule had an effect on cell cycle distribution, ultimately leading to cell cycle arrest. Cell cycle analysis was performed in NIH/3T3 cells transiently transfected with pEF6/V5-spacer, pEF6/V5-Spa310 or the control vector pEF6/V5. A marker plasmid expressing enhanced green fluorescent protein (EGFP)-spectrin was included in the transfection mixture. At 48 h after transfection, cells were fixed and stained with propidium iodide to determine the DNA content and were simultaneously examined for EGFP expression. Flow cytometry analyses indicated that the spacer and the Spa310 small molecule similarly induced a G 0 /G 1 arrest of the cell cycle, reducing the population of cells in the S phase ( Figure 5 ). This suggests that the Spa310 small molecule, similarly to the full-length spacer domain of pRb2/p130, acts as a growth suppressor by inducing a G 0 /G 1 arrest of the cell cycle. 
Control Spacer Spa310
Figure 2 Subcellular localization of Spacer and Spa310 molecules by immunofluorescent staining. NIH/3T3 cells were seeded on Nalge Nunc chamber slides and transfected the next day with pEF6/V5 vector, pEF6/V5-Spa310 or pEF6/V5-spacer. Immunofluorescence analysis of transfected cells with anti-V5 antibody revealed a localization of the tagged Spacer and Spa310 proteins in the cytoplasm and in the nucleus (red spots). Cells were counterstained with DAPI to visualize the nuclei (blue). The data shown are representative of three independent experiments. pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al
The Spa310 small molecule suppresses in vivo tumor formation The promising finding that Spa310 strongly inhibited cdk2 activity in vitro halting cellular growth by arresting cells in the G 0 /G 1 phase of the cell cycle prompted us to investigate its effect on tumor formation in nude mice. We designed four synthetic peptides based on the 39 amino acids identified, responsible for the inhibitory activity of cdk2 (Table 2) . Two synthetic peptides consisted of the Spa310 amino-acid sequence with or without the addition of a nuclear localization signal derived from HIV-1 Tat, as described previously (Vives et al., 1997) . The sequence of Spa310 was scrambled in the other two synthetic peptides to be used as controls (Scramble and Scramble-TAT peptides). The minimal nuclear localization signal of HIV-1 Tat was fused to the N-terminal of the synthetic peptides in order to allow efficient translocation through the plasma membrane, increasing nuclear accumulation. The functional anticdk2 activity of the peptides was tested in an in vitro kinase assay (data not shown) before injecting the tumor xenografts. When the tumor xenografts reached a volume of about 0.05 cm 3 they were treated with one of the four synthetic peptides: Spa310, Spa310-TAT, Scramble and Scramble-TAT. Tumor sizes were measured before each treatment, volume was calculated and plotted on a graph. Three-to four-fold reduction in tumor size was observed 30 days after the first injection of Spa130 (with or without Tat) with respect to the Scramble peptides (Figure 6 ). Interestingly, the addition of the Tat nuclear localization signaling did not influence the growth inhibitory activity of the Spa310 small molecule.
Discussion
One of the main goals in the development of novel therapeutics for proliferative disorders is to generate selective small molecules that potently inhibit cell cycle progression. Several studies have provided evidence of the critical involvement of cyclin/cdk complexes at specific cell cycle regulatory checkpoints (Morgan, 1997; Bagella et al., 2006) . Progression through the cell cycle is driven by activation and deactivation of cyclin/ cdk complexes, which start a fundamental cascade of events leading to DNA replication and chromosomal segregation. Tumor development is closely associated with alteration and deregulation of cdks and their regulators, suggesting that inhibitors of cdks may be useful anticancer therapeutics. Therefore, targeting cdk activity has become an attractive strategy in cancer therapy, as it could potentially create a rationally designed inhibitor of a specific process that leads a cell to malignant transformation. To date, several families of chemical inhibitors targeted against different cdk activities have been described (Losiewicz et al., 1994; Gray et al., 1998) and, for some of them, their anticancer therapeutic potential has been demonstrated in preclinical studies (Dai and Grant, 2004) . Recent attention has been focused on biological molecules, rather than chemotherapeutic agents, that combine the effectiveness of arresting cellular growth through interaction with important cell cycle checkpoint regulators, and the low risk of unexpected adverse reactions, thus improving clinical safety and patient tolerability. Therefore, development of pharmacological small molecules able to inhibit cdk activity could be an alternative mechanism-based therapy of great interest in the treatment of neoplasms or other proliferative disorders.
Cdk2 is known to be active in complex with cyclin E at the G 1 -S boundary, and in complex with cyclin A during S-phase progression (Shapiro, 2006) . Although it has been described that cdk2 is not an essential gene in the mouse, (Berthet et al., 2003; Geng et al., 2003; Ortega et al., 2003; Tetsu and McCormick, 2003) an overexpression of cdk2 with associated cyclins has been shown in several tumors (Al-Aynati et al., 2004; Olofsson et al., 2004) . Furthermore, cdk2 has been recently found to be required for centrosome duplication in mammalian cells (Matsumoto et al., 1999; Matsumoto and Maller, 2004) suggesting that inhibition of cdk2 activity would be an effective anticancer approach. In addition, cdk2 has rapidly emerged as a potential inhibition target by small molecule drugs that will hopefully lead to the development of effective therapies for proliferative disorders (Gibbs and Oliff, 1994; Senderowicz, 2003 We were therefore led to generate a molecular tool that provides a mechanism-based model for the inhibition of cdk2 activity. Previously, it was demonstrated that pRb2/p130, a member of the Rb family of proteins, acts during cell growth suppression as an inhibitor of cdk2 activity Howard et al., 2000) . The spacer region of pRb2/p130 has a unique amino-acid sequence among the other members of the Rb family, and it is responsible for this inhibitory effect on cdk2 (De Luca et al., 1997) . Here, we report the identification of a small molecule peptide, Spa310, based on the sequence of the pRb2/p130 spacer domain able to maintain its inhibitory effect on cdk2 activity, to retain its ability to induce growth arrest when expressed in cells TDYSPATRSVGITRPTLPTSRDSYTGRERSVGPLRTALT Primary structure of the synthesized peptides containing the 39 amino acids of the Spa310 are shown. One-letter codes are used. The TAT peptide domain, for cellular internalization, added to the 39-amino-acid sequence is represented in bold.
pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al and more importantly, to suppress tumor formation and progression in vivo. In order to identify the key residues that still exert a noteworthy inhibitory activity on cdk2, the length of the spacer domain was restricted to a critical region of 39 amino acids (aa 641-679). This region, which corresponds to a small peptide of about 5 kDa, completely retains the ability of the spacer domain to inhibit cdk2-dependent H1 kinase activity and similarly, when introduced into cells, it induces an inhibition of the endogenous cdk2 activity comparable to that induced by the full-length spacer domain. The effects of Spa310 expression on cellular proliferation were evaluated using colony formation assays. We observed that the inhibition of colony formation induced by Spa310 was surprisingly even greater than that induced by the full-length spacer (more than 50%). Comparable results have been found using the A2058 human melanoma cell line (data not shown). The Spa310-induced growth inhibition was associated with a considerable accumulation of cells in the G 0 /G 1 phase of the cell cycle, and a decrease in the number of S-phase cells, thus demonstrating that the small molecule maintains the growth suppressive properties of pRb2/ p130 in cells. This is consistent with a large body of literature showing the importance of the inhibition of cdk2 activity in cellular differentiation that accompanies cell accumulation in the G 0 /G 1 phase of the cell cycle (Carlson et al., 1996; Alessi et al., 1998; Lee et al., 1999) . Inhibition of cdk2 activity by Spa310 can, therefore, account for the G 0 /G 1 arrest observed following expression of the small molecule.
We finally examined the ability of the small molecule Spa310 to suppress tumor formation and progression. Our results, showing statistically significant reduction in the volume of tumor formation in nude mice have exciting implications for developing a drug design program aimed at producing small synthetic molecules that function as growth suppressors. The advantages of inhibiting rather than restoring the biochemical function of a protein that has lost its normal activity, combined with the commercial advantages of the biosynthetic process (i.e., low cost, simple techniques and the ability to produce molecules on a large scale), ultimately make the Spa310 small molecule a potentially significant pharmaceutical product in the treatment of hyperproliferative disorders.
Material and methods

Cell culture and transfections
The NIH/3T3 and A549 cell lines were obtained from the American Type Culture Collection (ATCC, Rochville, MD, USA). NIH/3T3 cells were grown at 371C, in a 5% CO 2 /95% atmosphere, in Dulbecco's modified Eagle's medium (Mediatech Inc., Herndon, VA, USA) supplemented with fetal bovine serum (FBS) (Mediatech Inc., Herndon, VA, USA). The A549 cell line non-small cell lung cancer cell line was cultured in Ham's F-12 with NaHCO 3 (0.75 g NaHCO 3 /500 ml of Ham's F-12) and 10% (vol/vol) FBS. The cells were cultured at 371C in a humidified incubator containing 5% CO 2 . Cells were harvested for animal use, when they reached 70-80% confluence. Transfections were performed using the Fugene transfectant reagent (Roche Applied Science, Indianapolis, IN, USA) according to the manufacturer's protocol.
Constructs preparation
A prokaryotic expression vector pGEX-2T (Stratagene Inc., La Jolla CA, USA) and polymerase chain reaction (PCR) were used to generate chimeric GST constructs. The primers used by PCR to amplify the fragments that were subcloned in the pGEX-2T were derived from the 5 0 and 3 0 ends of different regions of the spacer domain of pRb2/p130. The nucleotide and amino-acid positions, and the fragment length in base pairs and amino acids are shown in Table 1 . The mammalian expression vector pEF6/V5-His TOPO (Invitrogen Corp, Carlsbad, CA, USA) was used to generate the constructs pEF6/V5-His-spacer and pEF6/V5-His-310 that express the correspondent genes with a C-terminal V5 epitope. The spacer and the 310 fragments were PCR-amplified with the respective primers (Table 1) to generate 3 0 ends of the cDNAs without stop codons and were subsequently subcloned into pEF6/ V5-His TOPO (Invitrogen Corp, Carlsbad, CA, USA) pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al according to the manufacturer's instructions to obtain cDNAs coding for C-terminal fusion proteins. All generated constructs were confirmed by automated sequencing. Information regarding the primers is available upon request.
GST fusion protein preparation XL1-Blue bacteria carrying the pGEX-2T vectors were grown to mid log phase and then induced to express protein by adding 0.25 mM of isopropyl-1-thio-b-D-galactopyranoside (IPTG, Roche Applied Science, Indianapolis, IN, USA). The cultures were shaken for 4 h; bacteria were then pelleted and resuspended in NENT buffer (20 mM Tris (pH 8), 100 mM NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA), 0.5% NP-40). Cell suspensions were sonicated, pelleted and the supernatant collected. The remaining bacteria were then resuspended in NENT buffer plus 2% of N-lauryl-sarcosine, pelleted and the supernatants were collected again. The combined supernatants were incubated with glutathione agarose (Amersham Biosciences, Piscataway, NJ, USA) overnight at 41C. The agarose was then pelleted and washed three times in NENT buffer.
Kinase assays
Cell lysates from NIH/3T3 were prepared by resuspending pelleted cells in 500 ml of lysis buffer (50 mM Tris, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton, 0.1 mM Na 3 VO 4 , plus protease inhibitors). An equal amount of protein for each fraction (100 mg) was immunoprecipitated with a polyclonal anti-cdk2 antibody (De Luca et al., 1997) . The complexes were pulled down with protein A-Sepharose and washed three times with lysis buffer and twice with lysis buffer containing 400 mM NaCl. The complexes were equilibrated in kinase assay buffer (20 mM 4-(2-hydroxyethyl)-1-piperazineethyl-sulfonic acid (pH 7.4), 10 mM MgAc, 20, 1 mM dithiothreitol). In order to detect the in vitro inhibition of cdk2 activity, each sample was incubated with an equal amount (0.1 mg) of each pGEX-2T fusion protein, in a final volume of 20 ml of kinase buffer, using 5 mCi/sample of g-ATP (adenosine 5 0 triphosphate) (Amersham Biosciences, Piscataway, NJ, USA) and 2 mg of histone H1 for 30 min at 301C. Kinase assays were repeated at least three times, giving an inter assay standard deviation within 10% after normalization for protein amount. In order to evaluate the in vivo inhibition of cdk2 activity, cdk2 was immunoprecipitated, as described above, from NIH/3T3 cells transiently transfected with 5 mg of pEF6/V5-spacer, pEF6/V5-Spa310 or the vector alone as a control. The immunocomplexes were split in two tubes. A half of each sample was assayed for cdk2 activity in a final volume of 20 ml of kinase buffer with 5 mCi/sample of g-ATP and 2 mg of histone H1 for 30 min at 301C; the second one was tested in western blot analysis to confirm that all the samples contained the amount of cdk2 immunoprecipitated. Briefly, the samples were separated into 12% sodium dodecyl sulfate-polyacrylamide gels, and then transferred into a nitrocellulose membrane (Schleicher & Schuell, Dassel, Germany) . The membrane was blocked with 5% non-fat dry milk in 1 Â Tris-buffered saline with 0.1% Tween and incubated with the polyclonal anti-cdk2 antibody described above. Anti-rabbit peroxidase conjugated (1:10 000) (Amersham, IL, USA) and enhanced checiluminescence detection system (Enhanced Chemiluminescence Kit; Du Pont NEN, Boston, MA, USA) were used for the detection.
Immunofluorescence
Exponentially growing NIH/3T3 cells were seeded on two-well micro-chamber slides (Nunc, Naperville, IL, USA) and transfected the next day with 1 mg of pEF6/V5-spacer, pEF6/ V5-Spa310 or the vector alone as a control. Forty-eight hours after transfection, cells were fixed in phosphate-buffered saline (PBS)-buffered 4% paraformaldehyde for 15 min at room temperature and then permeabilized in 0.1% Triton X-100/ PBS before washing and blocking in 0.1% bovine serum albumin/0.1% Triton X-100/PBS in 371C for 30 min. The primary antibody used for immunofluorescence was an anti-V5 monoclonal antibody (Invitrogen Corp, Carlsbad, CA, USA) that recognizes the epitope present in the constructs. The secondary antibody was a goat anti-mouse conjugated with Alexa-568 (Molecular Probes, Eugene, OR, USA) used at a dilution of 1:2000. DNA was counterstained with DNA fluorochrome 4 0 , 6 0 diamedino-2-phenylindole (DAPI, Sigma Inc., St Louis, MO, USA) and slides were mounted with the SlowFade anti-fade reagent (Molecular Probes, Eugene, OR, USA). Negative controls were performed with secondary antibodies only. The slides were seen under an inverted Olympus IX70 microscope (Olympus America, Inc., Melville, NY, USA). Fluorescence images were captured with Sensicam QE camera (Cooke Co., Auburn Hills, MI, USA) and operated with SlideBook 3.0 software (Intelligent Imaging Innovations Inc., Denver, CO, USA) in order to eliminate the background haze and reveal individual foci.
Colony formation assay
Exponentially growing NIH/3T3 cells were seeded in 100-mm dishes at a density of 5 Â 10 5 cells per 100 mm dish the day before transfection. Cells were transfected with 5 mg of pEF6/ V5-spacer, pEF6/V5-Spa310 or the control vector pEF6/V5 carrying the brasticidin S-resistant gene (bsr) as a selectable marker gene. For selection, blasticidin S hydrochloride (Funakoshi, Tokyo, Japan) was added to the culture medium 48 h after transfection, at a final concentration of 10 mg/ml. After 6 days, 1 Â 10 3 of blasticidin S-resistant cells in each well were plated in triplicate in 60-mm dishes, in order to evaluate their colony-forming ability. Cells were then incubated at 371C for 8 days in a selecting medium containing blasticidin S hydrochloride at a final concentration of 10 mg/ml. Colonies, defined as groups of a minimum of 50 cells, were counted after staining with 2% methylene blue in 95% ethanol.
Cell cycle analysis by flow cytometry Cells were transiently transfected with 5 mg of pEF6/V5-spacer, pEF6/V5-Spa310 or the vector alone as a control. A marker plasmid expressing EGFP-spectrin was included in the transfection mixture. Control cells, which were not transfected with EGFP-spectrin, were used as the EGFP-negative population. Cells were harvested and examined for their cell cycle states by fluorescence-activated cell sorter (FACS) analysis. After harvest, cells were fixed by adding ice-cold 70% ethanol while vortexing. Fixed cells were stored at 41C for at least 30 min and then washed once with PBS. Cells were then stained with 10 mg/ml propidium iodide (Roche Applied Science, Indianapolis, IN, USA), 250 mg/ml RNase (Sigma, St Louis, MO, USA) in PBS and incubated at 371C for 30 min in the dark. Transfected cells were gated according to their EGFP expression and the DNA content was determined by flow cytometry analysis. The percentage of cells in the different phases of the cell cycle was measured with a FACS Calibur instrument (Becton-Dickinson, San Jose, CA, USA) and the data obtained were analysed by WinMDI 2.8 software.
Preparation of tumor xenografts in immunodeficient mice
The animal experiments were carried out in accordance with the Guidelines for the Care and Use of Laboratory Animals (National Institute of Health publication number 85-23) and pRb2/p130 small molecule leads to cellular growth arrest L Bagella et al the institutional guidelines of Temple University. Four-sixweek-old female athymic nude mice (CD1, nu/nu) were purchased from Charles River Laboratory (Wilmington, MA, USA). About a week after the mice arrived, the A549 cells were harvested and then suspended in unsupplemented culture medium without FBS. After the mice were anesthetized by isoflurane inhalation, 4 Â 10 6 cells in a final volume of 100 ml were injected subcutaneously into the left flank of each mouse by using 1-ml syringes with 25.5-gauge needles.
In vivo analysis of synthetic peptide effects on tumor growth Animal weight was monitored weekly. The length and width of each tumor were measured every time in triplicates by using a Vernier caliper. The median of the measurements was applied to the following formula to calculate tumor volumes: tumor volume ¼ (the length of the tumor Â the width of the tumor) 2 /2. When the tumors grew to a volume of about 0.05 cm 3 , the mice were treated with the peptides. The peptides were chemically synthesized by the Jefferson Protein/Peptide Chemistry/ Molecular Interaction Facility (Philadelphia, PA, USA). Four peptides were tested in the in vivo experiments (Spa310, Spa310-TAT, Scramble and Scramble-TAT). Mice were treated with 50 ml of each 1.5 mM peptide in distilled water injected into the tumor every 4 days. The tumor sizes were measured before each treatment. Tumor volumes were calculated and plotted on a graph. This study was repeated under exactly the same conditions.
